RGEN News and Press, Repligen Corporation From 04/27/22

Repligen press release (NASDAQ:RGEN): Q1 Non-GAAP EPS of $0.92 beats by $0.20. Revenue of $206.4M (+44.5% Y/Y) beats by $20.92M. GAAP gross margin was 60.1%, an increase of 190 bps; Adjusted (non-GAAP) gross margin was 60.4%, an increase of 100 bps. GAAP operating margin was 29.1%, an increas...

—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business s...

Repligen (NASDAQ:RGEN) is scheduled to announce Q1 earnings results on Tuesday, April 27th, before market close. The consensus EPS Estimate is $0.72 (+5.9% Y/Y) and the consensus Revenue Estimate is $185.48M (+29.9% Y/Y). Over the last 2 years, RGEN has beaten EPS estimates 100% of the time a...

Much has been written about the life sciences industry in the wake of COVID-19. The bottom line is that the bar for speed of innovation, regulation, and collaboration has been forever raised. With a renewed interest in science, the companies behind the research and development process s...

WALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022. The Company will issue a press release before the market opens and will host a conference...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Of all the images that come to mind when we think of space flight, few are as iconic as the Space Shuttle soaring upward, its twin rocket boosters blasting out fire. Source: NASA If you’re familiar with this image, ...

With long-term investing, time is on your side. There is beauty in the fact that you can ignore the short-term market gyrations and instead focus on quality companies in growing markets . While some biotechs can be risky, not all are dependent upon clinical trial outcomes . That...

Repligen Corporation (RGEN) Q4 2021 Earnings Conference Call February 17, 2021 8:30 am ET Company Participants Tony Hunt - President, Chief Executive Officer Jon Snodgres - Chief Financial Officer Sondra Newman - Head of Investor Relations Conference Call Participants Dan Arias - Stifel Jacob...

Repligen press release (NASDAQ:RGEN): Q4 Non-GAAP EPS of $0.81 beats by $0.16. Revenue of $186.52M (+71.7% Y/Y) beats by $8.25M. For FY2022, the company expects total revenue is expected to be in the range of $800M-$830M vs. consensus of $801.51M, reflecting overall revenue growth of 19%-24% ...

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021 ...